Cowen Anticipates Dynavax’s Now-Approved Heplisav Will Lead the HBV Vaccine Market Sun, 12 Nov 2017 23:49:32 +0000 Dynavax Technologies (NASDAQ:DVAX) after five years of "torturous" waiting has at long last garnered FDA approval for Heplisav-B. Cowen analyst Phil Nadeau anticipates hundreds of millions of dollars to be made in the HBV vaccine market within 5 years.
At Long Last, Dynavax Wins FDA Approval For Heplisav Fri, 10 Nov 2017 13:44:17 +0000 Dynavax Technologies Corporation (NASDAQ: DVAX ), a clinical-stage immunotherapy company, confirmed on Thursday the U.S. Food and Drug Administration approved its two-dose vaccine The company failed to ...
Dynavax stock surges 18% on hepatitis B vaccine approval Fri, 10 Nov 2017 12:19:17 +0000 Dynavax Technologies Corporation shares surged 18% in premarket trade Friday after the company said its hepatitis B vaccine was approved by the Food and Drug Administration. The vaccine, Hepislav-B, is ...
Third time's the charm: East Bay drug maker wins FDA approval for hepatitis B vaccine Thu, 09 Nov 2017 22:44:45 +0000 An easier-to-take vaccine from an East Bay company, which could shift the fight against the surging, deadly hepatitis B virus, won regulatory approval Thursday. The company has spent hundreds of millions of dollars trying to develop the vaccine over more than a dozen years. The FDA rejected Heplisav B in February 2013 and delayed approval a year ago in order to study late-arriving data more closely.
Dynavax Technologies Corporation’s (DVAX) Hepatitis B Vaccine Wins FDA Approval Thu, 09 Nov 2017 22:12:53 +0000 Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S. Food and Drug Administration approval for its hepatitis B vaccine, HEPLISAV, ending a more than nine-year effort to bring the vaccine to the market. Dynavax shares reacted to the FDA approval, rising nearly 16% to $23.25 in after-hours trading. Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.